CClinicalTrials.gg
RecruitingNCT05386927Updated Oct 19, 2023

Early Diagnosis of GDM by Multiomics

An observational study in Gestational Diabetes Mellitus, sponsored by Women's Hospital School Of Medicine Zhejiang University. Recruiting at 1 site in China. Open to female participants aged 20 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-19.

Sponsored by Women's Hospital School Of Medicine Zhejiang University · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 9 months ago, but the record still lists the study as recruiting.
  • Started May 2022; still recruiting 4 years 5 months later.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
5,000
Ages
20 Years to 49 Years
Sex
Female
01

Study summary

Gestational diabetes mellitus (GDM) is prone to cause a variety of adverse pregnancy outcomes, and has potential harm to the short-term and long-term health of both mothers and infants. However, its diagnosis mainly relies on oral glucose tolerance test (OGTT) at 24-28 weeks of gestation, so it is often diagnosed in the second and third trimester, and may be too late to intervene. Therefore, advancing the diagnostic window period of GDM is the key to the prevention and treatment of GDM and its complications. It is urgent to establish a new technology for the early diagnosis and screening of GDM with high detection rate and accuracy. Based on literature survey and previous studies, this study found that the combined analysis of metabolomics and lipidomics may have broad clinical application prospects in the early diagnosis and screening of GDM. It is hoped that a set of new techniques based on multi-omics for early diagnosis and screening of GDM can be constructed, providing a feasible and effective tool for early detection and treatment of GDM in clinical.

02

Conditions studied

  • Gestational Diabetes Mellitus

Browse trials for

03

In context

Diabetes, Gestational

842 studies on the registry are indexed under Diabetes, Gestational; 198 are open to participants now.

This study's planned enrollment of 5,000 is above the median of 200 across 269 observational studies indexed under Diabetes, Gestational.

Browse Diabetes, Gestational studies →

Lead sponsor

Women's Hospital School Of Medicine Zhejiang University is the lead sponsor of 74 studies on the registry; 44 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 49 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

This project intends to recruit pregnant women who go to the research center for routine prenatal examination and OGTT screening.

Inclusion criteria

  • Plan to have routine prenatal examinations and give birth in the research center
  • First trimester
  • Singleton pregnancy
  • Without pregnancy complications
  • Willing to cooperate with the hospital to follow up

Exclusion criteria

Exclusion Criteria:

  • Have diseases that affect metabolic function or even threaten the life of the mother and fetus before pregnancy, such as diabetes, heart disease, liver and kidney diseases, thyroid diseases with drug, autoimmune diseases, malignant tumors, AIDS, etc.
  • Fetus has a known deformity or genetic defects
  • Incomplete clinical data
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
5,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • GDM group

    Pregnant women with positive OGTT results at 24-28 gestational weeks

    Other: Questionnaire survey and specimen collection

  • Control group

    Pregnant women with negative OGTT results at 24-28 gestational weeks, and had baseline data that matched those in the GDM group

    Other: Questionnaire survey and specimen collection

Interventions

  • OtherQuestionnaire survey and specimen collection

    A questionnaire survey was conducted when pregnant women were enrolled in the first trimester, and blood, urine, saliva and other specimens were collected.

06

What researchers measure

Primary outcomes

  1. Salivary metabolomics

    The differential salivary metabolism molecules in saliva were detected by the self-developed detection chip, and the markers related to GDM in early pregnancy were screened. Specimens were collected during the first trimester.

    Time frame: First trimester (9-14 gestational weeks)

  2. Serum lipidomics

    The differential serum lipid molecules in serum were detected by the self-developed detection chip, and the markers related to GDM in early pregnancy were screened. Specimens were collected during the first trimester.

    Time frame: First trimester (9-14 gestational weeks)

  3. Urine metabolomics

    The differential urine metabolism molecules in urine were detected by the self-developed detection chip, and the markers related to GDM in early pregnancy were screened. Specimens were collected during the first trimester.

    Time frame: First trimester (9-14 gestational weeks)

07

Study locations

1 of 1 sites recruiting
  • Women's Hospital School Of Medicine Zhejiang University
    Hangzhou, Zhejiang 310006, China
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05386927
Lead sponsor
Women's Hospital School Of Medicine Zhejiang University
Responsible party
Sponsor
First posted
May 23, 2022
Start date
May 1, 2022
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Oct 19, 2023

Study contacts

Zhaoxia Liang, Prof.
Contact
xiaozaizai@zju.edu.cn
86571-89992115
Zhaoxia Liang, Prof.
study director · Women's Hospital School Of Medicine Zhejiang University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion